Expanding Product Portfolio: The iStent portfolio significantly boosted Glaukos' glaucoma franchise revenues in 2024. Additionally, the launch of iDose TR in the second quarter of 2024 is already ...

Minimally invasive glaucoma surgeries, like the iStent inject and Xen Gel Stent, are crucial for preventing disease progression. Technological innovations, including AI-driven diagnostics and ...

to revolutionize the traditional glaucoma treatment and management paradigm. Glaukos launched the iStent, its first MIGS device, in the United States in 2012, its next-generation iStent inject ...

With over 20 years of experience, he has pioneered minimally invasive glaucoma surgeries (MIGS), including Trabectome, iStent and canaloplasty, transforming patient care. His research also focuses ...

It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.

GKOS is well-positioned to capitalize on the growing need for interventional glaucoma therapies and minimally invasive procedures. Key products such as iDose TR, iStent Infinite, and Epioxa are ...